N-[4-(4-methoxy-3-methylphenyl)-1,3-thiazol-2-yl]-3-methylpyridin-2-amine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: N-[4-(4-methoxy-3-methylphenyl)-1,3-thiazol-2-yl]-3-methylpyridin-2-amine
• 英文别名: 4-(4-methoxy-3-methylphenyl)-N-(3-methylpyridin-2-yl)-1,3-thiazol-2-amine
• 化学式: C₁₇H₁₇N₃OS
• 分子量: 311.4
• InChiKey: FZHKNEWQWRWDJI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  75.3
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Ligase E3 RNF185 inhibitors and uses thereof
  申请人：Commissariat à l'Énergie Atomique et aux Énergies Alternatives

  公开号：EP2835423A1

  公开（公告）日：2015-02-11

  The present relates to the use of an E3 ligase RNF185 inhibitor for treating cystic fibrosis and chronic obstructive pulmonary disease.

  本发明涉及一种用于治疗囊性纤维化和慢性阻塞性肺病的 E3 连接酶 RNF185 抑制剂。
• LIGASE E3 RNF185 INHIBITORS AND USES THEREOF
  申请人：Commissariat à l'Energie Atomique et aux Energies Alternatives

  公开号：EP3030657B1

  公开（公告）日：2018-07-18
• Compounds Having Activity in Correcting Mutant-Cftr Processing and Uses Thereof
  申请人：Verkman Alan

  公开号：US20080318984A1

  公开（公告）日：2008-12-25

  The invention provides compositions, pharmaceutical preparations and methods for correcting cellular processing (e.g., folding, trafficking, or post-translational modification) of a mutant-cystic fibrosis transmembrane conductance regulator protein (e.g., ΔF508 CFTR) that are useful for the treatment of cystic fibrosis (CF). The compositions and pharmaceutical preparations of the invention may comprise one or more aminobenzothiazole-containing compounds, aminoarylthiazole-containing compounds, quinazolinylaminopyrimidinone-containing compounds, bisaminomethylbithiazole-containing compounds, or phenylaminoquino-line-containing compounds of the invention, or an analog or derivative thereof.
• A CFTR CORRECTOR FOR THE TREATMENT OF GENETIC DISORDERS AFFECTING STRIATED MUSCLE
  申请人：UNIVERSITA' DEGLI STUDI DI PADOVA

  公开号：US20150328217A1

  公开（公告）日：2015-11-19

  The present invention relates to the use of CFTR correctors in the treatment of genetic disorders affecting striated muscle selected from sarcoglycanopathies, Brody's disease (BD) and the recessive forms of Cathecolaminergic Polymorphic Ventricular Tachycardia (CPVT).
• CFTR CORRECTOR FOR THE TREATMENT OF GENETIC DISORDERS AFFECTING STRIATED MUSCLE
  申请人：UNIVERSITA' DEGLI STUDI DI PADOVA

  公开号：US20180221347A1

  公开（公告）日：2018-08-09

  The present invention relates to the use of CFTR correctors in the treatment of genetic disorders affecting striated muscle selected from sarcoglycanopathies, Brody's disease (BD) and the recessive forms of Cathecolaminergic Polymorphic Ventricular Tachycardia (CPVT).